TB-500 is a short fragment related to thymosin beta-4 and is claimed to speed tendon, ligament and muscle recovery.
What TB-500 does and why that matters
TB-500 is commonly identified as a short fragment of thymosin beta-4, a larger natural protein involved in cell movement and wound repair. TB-500 is claimed to speed tendon, muscle and ligament healing. Research on full-length thymosin beta-4 does not prove that the shorter fragment has the same action, reaches an injury or improves pain and recovery in people. [1,2,3]
Function evidence: Fragment identity established; human repair benefit not established
What people hope to notice
TB-500 is claimed to reduce pain, improve movement and speed recovery from tendon, ligament or muscle injuries. The cited TB-500 paper did not test those outcomes; it identified the fragment and its metabolites in horses for doping-control purposes. Human wound research on full-length thymosin beta-4 studies a different molecule and cannot be transferred to the shorter fragment. There is no controlled human evidence showing that TB-500 reaches an injured site, repairs tissue or shortens recovery. [1,2,3]
What supports this description: Unverified claims plus nonhuman detection research; human recovery outcomes untested
TB-500 Dosing status
Dose: No established human therapeutic dose | Frequency: No validated treatment schedule | Cycle: No established loading, maintenance or cycling regimen | Route: No approved human route
Preparation: No FDA-approved preparation instructions.
The cited sources do not establish a human dosing regimen, a recovery timeline or a shelf life after mixing for this fragment. [1,2,3]
TB-500 Effects
What the TB-500 study tested. The cited analytical study identified the fragment and its metabolites in horses after administration. It was a detection study, not a human trial of recovery, injury treatment or hair growth. [1]
Related wound research. The venous-ulcer trial studied full-length thymosin beta-4. It does not validate injecting the TB-500 fragment for tendon injuries or whole-body recovery. [3]
TB-500 Side Effects
Safety remains uncertain. FDA flags potential immunogenicity, aggregation and peptide-impurity concerns, and reports no identified human exposure data for drug products containing the fragment. These gaps do not establish that it is safe. [2]
Frequently Asked Questions About TB-500
How does TB-500 relate to thymosin beta-4?
The fragment identified as TB-500 is an acetylated seven-residue segment of the 43-residue protein. Their evidence should be assessed separately. [1,3]
Does combining TB-500 with BPC-157 have established benefits?
The sources cited here do not establish the safety or effectiveness of that combination in controlled human trials. The term Wolverine stack describes an informal combination, not a validated treatment. [1,2,3]
Evidence
Human treatment evidence not established. Analytical research identified TB-500 as an acetylated seven-residue fragment. FDA reports no identified human exposure data for drug products containing the thymosin beta-4 fragment. Studies of the full-length protein address a different substance. [1,2,3]
Approval status: No FDA-approved TB-500 product
References
Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. Journal of Chromatography A, 2012. PMID 23084823
U.S. Food and Drug Administration Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks FDA, 2026. Source
Guarnera G, et al. Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing. Ann N Y Acad Sci, 2007. PMID 17495250
Storage
Educational evidence summary. Approval applies only to the named product and indication; compounded, investigational, and research-market products are different categories.
◇An FDA-approved label or a patient-specific prescription from a licensed pharmacy
◇The active ingredient, strength, dosage form, concentration, lot, and dispensing instructions
◇Identity or purity tests only support the tests performed; they do not prove sterility, endotoxin safety, dose accuracy, stability, or clinical suitability
◇A “research use only” vial is not a patient medicine
